We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
151
CALL
Tvardi Therapeutics
TVRD
$24.3M
– –
-2,778
Closed -$1.54M
CDMO
152
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-3,476
Closed -$15K
EGRX
153
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-100,000
Closed -$7.89M
DMK
154
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-5,714
Closed -$2.08M
ZYNE
155
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-100,000
Closed -$10.2M
SYNH
156
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-8,532
Closed -$499K
ACOR
157
DELISTED
Acorda Therapeutics
ACOR
– –
-265
Closed -$626K
SIOX
158
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-37,500
Closed -$6.96M
SIOX
159
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-71,588
Closed -$13.3M
LHCG
160
DELISTED
LHC Group LLC
LHCG
– –
-10,730
Closed -$728K
RDUS
161
DELISTED
Radius Health, Inc.
RDUS
– –
-645,873
Closed -$29.2M
RDUS
162
PUT
DELISTED
Radius Health, Inc.
RDUS
– –
-200,000
Closed -$9.05M
HRC
163
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-7,930
Closed -$631K
DPLO
164
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-30,658
Closed -$454K
WCG
165
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-5,056
Closed -$908K
FWP
166
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-27,817
Closed -$3.96M
ONSIW
167
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
– –
-462,500
Closed -$80K
ONSIZ
168
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
– –
-462,500
Closed -$42K
3 4 5 6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.